All In Biotech

Drug Trial Radar · NCT05420454

A Study for the Neoadjuvant Treatment of Breast Cancer

A Prospective, Open-label Study to Evaluate Injectable Albumin-bound Paclitaxel Versus Docetaxel for the Neoadjuvant Treatment of Breast Cancer

Last checked: Nov 20, 2026Latest source record: Jul 1, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 1,576 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,576

Planned (sponsor's estimate)

Start

Jul 10, 2022

Primary completion

Jun 10, 2027

Study completion Dec 20, 2027

Sponsor

Sponsor type
Academic, hospital or other
First posted
Jun 15, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Due to the unique advantages of albumin-bound paclitaxel, several studies in China and abroad have tried to use albumin-bound paclitaxel for neoadjuvant treatment of breast cancer up to now. However, comparative studies between paclitaxel and docetaxel are still rare, In this study, a prospective, randomized, open-label, multi-center clinical study was conducted to analyse the efficacy and safety of albumin-bound paclitaxel and docetaxel in the neoadjuvant treatment of breast cancer, and to further analyse the efficacy and safety of albumin paclitaxel in combination with chemotherapy for postoperative breast cancer in different subtypes of breast cancer patients, in order to obtain more realistic data and provide new treatment options for breast cancer patients.

Conditions

  • Breast Cancer

Interventions

  • DocetaxelDrug

    75 mg/m2, d1, q3w,6 cycles

  • CarboplatinDrug

    AUC 6, d1, q3w ,6 cycles

  • TrastuzumabDrug

    starting dose 8 mg/kg, maintenance dose 6 mg/kg, d1, q3w ,6 cycles

  • PertuzumabDrug

    starting dose of 840 mg, maintenance dose of 420 mg, d1, q3w,6 cycles

  • Nab paclitaxelDrug

    220 mg/m2, d1, q3w,6 cycles

  • EpirubicinDrug

    90 mg/m2,d1, q3w × 4 cycles,followed by docetaxel

  • CyclophosphamideDrug

    600 mg/m2, d1, q3w ,4 cycles,followed by docetaxel

  • DocetaxelDrug

    100 mg/m2, d1, q3w × 4 cycles

  • EpirubicinDrug

    90 mg/m2,d1, q2w × 4 cycles,followed by nab-paclitaxel

  • CyclophosphamideDrug

    600 mg/m2, d1, q2w × 4 cycles followed by nab-paclitaxel

  • Nab paclitaxelDrug

    125 mg/m2, d1,8,15, q3w× 4 cycles

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. pCR(pathological complete response)Time frame: 1year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • 2nd Affiliated Hospital, School of Medicine, Zhejiang University

    Hangzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.